Related Experiment Video
Updated: May 8, 2026
06:58
Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
Alzheimer's in the workplace: a challenge for social work
Carole B Cox1, Manoj Pardasani
1a Graduate School of Social Service , Fordham University , New York , New York , USA.
Journal of Gerontological Social Work
|September 7, 2013
Summary
Alzheimer's disease and related disorders (ADRD) affect millions, including younger individuals. This study explores how employers manage employees experiencing cognitive impairment or caring for someone with ADRD.
Area of Science:
- Gerontology
- Occupational Health
- Neuroscience
Background:
- Alzheimer's disease and related disorders (ADRD) impact over 5.3 million Americans, with a significant portion being younger than 65.
- The prevalence of ADRD is projected to increase by 350% by mid-century, highlighting an urgent public health concern.
- Existing research on organizational policies primarily focuses on caregivers, leaving a gap in understanding employer responses to employees with ADRD symptoms.
Purpose of the Study:
- To investigate employer responses to dementia impacting employees.
- To examine how organizations address employees with cognitive impairment due to ADRD.
- To understand organizational strategies for supporting employees who are caregivers for individuals with ADRD.
Main Methods:
- Pilot study design.
- Qualitative or quantitative data collection on employer practices (specifics not detailed in abstract).
- Focus on workplace policies and support systems for affected employees.
Main Results:
- Preliminary findings on current employer practices regarding ADRD in the workplace (details not provided).
- Identification of challenges and successes in managing employees with cognitive decline or caregiving responsibilities.
- Insights into the need for improved organizational support and policies.
Conclusions:
- There is a critical need for organizations to develop and implement supportive policies for employees affected by ADRD.
- Addressing the impact of dementia in the workplace is essential for both employee well-being and organizational productivity.
- Further research is needed to comprehensively understand and address the multifaceted challenges of ADRD in the workforce.
Related Concept Videos
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...